Illumina (ILMN) Jumps 24.8% on Earnings Beat

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the best-performing stocks on Friday.

Illumina rallied for a second day on Friday, climbing 24.78 percent to close at $123.54 apiece after beating its earnings guidance in the third quarter of the year and projecting a lower revenue decline in the full fiscal 2025 period.

In an updated report, Illumina, Inc. (NASDAQ:ILMN) saw net income fall by 79 percent to $150 million from $705 million previously, as revenues ended flat at $1.08 billion.

“Illumina team delivered Q325 results that exceeded the high-end of our guidance range for revenue and earnings, driven by revenue acceleration in clinical, our largest market segment,” said CEO Jacob Thaysen.

Illumina (ILMN) Jumps 24.8% on Earnings Beat

RAJ CREATIONZS / shutterstock.com

“During the quarter, we returned to growth ex-China and are executing on our strategic pillars that support our long-range financial targets,” he added.

For fiscal year 2025, Illumina, Inc. (NASDAQ:ILMN) now expects revenues to decline by only 0.5 percent to 1.5 percent year-on-year, a revision of the upper end range of 2.5 percent previously.

Illumina, Inc. (NASDAQ:ILMN) is one of the leading genomics companies that engages in providing DNA sequencing and array-based technologies for life sciences, oncology, and reproductive health, among others.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.